Detalle Publicación

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Autores: Moreau, P. (Autor de correspondencia); Sonneveld, P.; Boccadoro, M.; Cook, G.; Mateos, M. V.; Nahi, H.; Goldschmidt, H.; Dimopoulos, M. A.; Lucio, P.; Blade, J.; Delforge, M.; Hajek, R.; Ludwig, H.; Facon, T.; San Miguel Izquierdo, Jesús; Einsele, H.
Título de la revista: HAEMATOLOGICA
ISSN: 0390-6078
Volumen: 104
Número: 12
Páginas: 2358 - 2360
Fecha de publicación: 2019
Adoptive cellular therapy using chimeric antigen receptor T-cell (CAR-T) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.